Interesting to follow the public face of PRR recently. In the...

Interesting to follow the public face of PRR recently.

In the last couple of years PRR have attended and/or presented at multiple conferences in the US. Some of these conferences seemed to coincide with appearances by Dendreon. The chance to present PRR's story to an audience that understands DNDN was an obvious benefit.

I've read second hand suggestions in these threads, that PRR management have been advised not to spruke the company in the US during the dual listing process. If that's the case it seems that they have acted on the advice.

There are several large biotech conferences in the US, Europe and Asia over the next couple of months. I may have missed something, but the only activity I can find for PRR is:
1. Prima attending (but not presenting) at Trout's "Wall Street Unplugged" conference in US this week.
http://www.troutgroup.com/wsu2011.aspx

2. Lucy Turnbull is keynote speaker at BioForum 2011 on August 17th in Melbourne.
https://www.ausbiotech.org/events/details.asp?eventid=935&returnToUrl=%2Fevents%2Fdefault.asp

3. Dr Neil Frazer is speaking at the ARCS Annual Scientific Congress in Canberra on 16 September
http://arcsconferences.com/program-2/f7/

So the company's actions seem to match the apparent SEC directive. Otherwise, with critical IIb trial results and other announcements due out soon, I'd expect them to be in the US, shouting from the rooftops.

Prima's SP is drifting, as biotechs tend to do between announcements. It's times like these that people get egdy! But given the state of the market and US related jitters, it's probably not doing too badly. Anyway, if you're a trader, there could be some good opportunities coming up. For long term holders like me, if you have faith in PRR's portfolio, it might be time to sit tight and just wait for announcements (or concentrate on something else for a while).

Good luck all.